Learn if You Have a Claim Against GlaxoSmithKline

GlaxoSmithKline Updates Paxil and Paxil CR Prescribing Information GlaxoSmithKline and the FDA notified physicians of changes to the pregnancy/precautions section of the prescribing information for Paxil and Paxil CR Controlled-Release Tablets. Glaxo's studies suggest Paxil may be more likely to be linked to birth defects than similar drugs.
Claimant Information

Are you submitting this information on behalf of yourself?	Yes No
Are you submitting this information on behalf of a family member?	Yes No
If yes, please provide: Name of Paxil User
Age of Paxil User
Relationship to Paxil User
Paxil Use

Date you began taking Paxil:
Date you stopped taking Paxil:
Medical Information

Did you take Paxil during your pregnancy?	Yes No
Did your infant suffer any birth defects that may have resulted from your Paxil use?	Yes No
If yes please describe.
Are you presently covered by health insurance?	Yes No
Have you previously retained an attorney to represent you in this matter?	Yes No

Personal Information

First Name

Last Name

Street / Apt /

City, State Zip

Home Phone & Evening Phone (Same) . . & . .

E-Mail Address

Confirm E-Mail

Date Issue/Problem

Terms & Conditions
I acknowledge that I have read and understand and agree to the following legal policies.

Certain features of Lawcash.com require a login - please simply choose a password to continue.

Password

Confirm Password

I'd like to become a Lawcash.com member, receive a free class action ebook, and free class action and recall alerts. Billions of dollars are available each year and I'd like to claim my fair share from bad corporations.

Submit

Other Drugs / Medical Cases of Interest

PolyMedica Announces Possible Financial Restatement

A class action has been filed against direct-to-consumer specialty medical products provider PolyMedica Corporation (Nasdaq: PLMD) and certain of its officers and directors by stockholders who purchased the company's common stock between July 23, 2001, and June 30, 2003.

Titan Pharmaceuticals Allegedly Overstated Prospects for Success of Proposed New Drug Iloperidone

A class action has been filed against biopharmaceutical company Titan Pharmaceuticals, Inc. (AMEX: TTP) and certain of its officers and directors by stockholders who purchased the company's common stock between December 1, 1999, and July 22, 2002. The action claims that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.

Cold Remedies Zicam and Cold-Eeze Linked to Loss of Ability to Smell and Taste

Kahn Gauthier Swick is seeking persons who have used over-the-counter homeopathic nasal solutions Zicam or Cold-Eeze, and who have suffered an intense burning sensation in their nasal cavities immediately after using either of the products followed by a loss of smell and taste long after they were over their cold. If you or a loved one has used either of these preparations, please contact Kahn Gauthier for more information.

Aetna Heath Insureds in Pennsylvania Claim that Liens against Tort Recovery Are Invalid

A class action has been filed against Aetna Health, Inc., a subsidiary of healthcare giant Aetna, Inc., on behalf of Pennsylvania residents (1) who, between September 26, 1999, and the date of the final judgment in the action, were injured in a motor vehicle accident while insured under an Aetna heathcare plan; and (2) whose tort recovery from the accident was subject to a lien asserted by Aetna. The action seeks compensatory and statutory damages for monies collected via the liens as well as injunctive and declaratory relief.

Manhattan Trio Drugs Pharmacy Users Allege Privacy Violations in Records Sale to CVS

State and federal privacy laws protect your confidential records from sale and use in many situations. A class action has been filed against CVS Corporation, Trio Drugs Corporation, and Manhattan pharmacist Gerald Hinderstein on behalf of pharmacy customers who allege that Trio and its pharmacist violated their fiduciary duties to their customers and committed deceptive business practices when they sold prescription drug records to CVS.

Synovis Life Technologies Misled Investing Public

Several class actions have been filed against medical device company Synovis Life Technologies, Inc., (Nasdaq:SYNO) and certain of its officers and directors by stockholders who purchased the company's common stock between October 16, 2003, and May 18, 2004. The actions claim that the defendants violated federal securities laws by issuing a series of material misrepresentations to the market over this time period, thereby artificially inflating the price of the company's securities.